View in EDS PDF Full Text

First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.

Saved in:
Bibliographic Details
Title: First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake.
Authors: Pandit-Taskar, Neeta1,2 pandit-n@mskcc.org, O'Donoghue, Joseph A.3, Ruan, Shutian1, Lyashchenko, Serge K.4, Carrasquillo, Jorge A.1,2, Heller, Glenn5, Martinez, Danny F.6, Cheal, Sarah M.7, Lewis, Jason S.1,2,4,7, Fleisher, Martin8, Keppler, Jennifer S.9, Reiter, Robert E.9, Wu, Anna M.9, Weber, Wolfgang A.1,2, Scher, Howard I.6,10, Larson, Steven M.1,2,7, Morris, Michael J.6,10
Source: Journal of Nuclear Medicine. Dec2016, Vol. 57 Issue 12, p1858-1864. 7p. 2 Color Photographs, 1 Black and White Photograph, 1 Diagram, 1 Chart, 4 Graphs.
Database: Engineering Source
Description
ISSN:01615505
DOI:10.2967/jnumed.116.176206